uniQure and Apic Bio enter into global licensing agreement for APB-102, a clinical stage gene therapy for patients with ALS caused by mutations in SOD1GlobeNewsWire • 01/31/23
uniQure announces positive CHMP opinion for etranacogene dezaparvovec – gene therapy for adults with hemophilia BGlobeNewsWire • 12/16/22
uniQure Highlights Therapeutic Potential of AMT-260 in Refractory Temporal Lobe Epilepsy (rTLE) at Virtual Research & Development EventGlobeNewsWire • 11/29/22
uniQure (QURE) Partner Gets FDA Nod for Hemophilia B Gene TherapyZacks Investment Research • 11/23/22
The FDA Just Approved The Most Expensive Drug Ever — Sending UniQure Stock On A WarpathInvestors Business Daily • 11/23/22
uniQure announces FDA approval of first gene therapy for adults with hemophilia BGlobeNewsWire • 11/22/22
U.S. Food and Drug Administration approves CSL's HEMGENIX® (etranacogene dezaparvovec-drlb), the first gene therapy for hemophilia BPRNewsWire • 11/22/22
uniQure to Host Virtual Research & Development Event on Tuesday, November 29, 2022GlobeNewsWire • 11/17/22
VectorY Appoints Sander van Deventer as CEO and Makes Key Appointments to Its Leadership TeamBusiness Wire • 11/08/22
Next-Generation mRNA, Gene Therapy, Plasma Products, Monoclonal Antibodies, and Recent Acquisitions and Collaborations Highlight CSL R&D Day 2022PRNewsWire • 11/02/22
uniQure Announces Third Quarter 2022 Financial Results and Highlights Recent Company ProgressGlobeNewsWire • 11/02/22
Analysts Estimate uniQure (QURE) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 10/17/22
uniQure Announces Multiple Presentations at the Upcoming Annual Meeting of The European Society of Gene and Cell Therapy (ESGCT)GlobeNewsWire • 10/11/22
uniQure Announces Second Quarter 2022 Financial Results and Highlights Recent Company ProgressGlobeNewsWire • 08/08/22